MK-8748 for Macular Edema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a new medicine, MK-8748 (an experimental treatment), can treat diabetic macular edema (DME) as effectively as the standard treatment, aflibercept. DME can cause vision problems for people with diabetes, and current treatments don’t work for everyone. Participants will receive either a low or high dose of MK-8748 or the standard dose of aflibercept. Those who have experienced diabetes-related vision changes, known as DME, and have been diagnosed or treated within the last three years may be suitable candidates for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have recently started new diabetes medications, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
A previous study found aflibercept to be generally safe for people with diabetic macular edema. Some participants experienced mild eye-related side effects, such as redness or discomfort, while more serious issues were less common.
Specific information about the safety of MK-8748 is limited. However, this trial is in a late stage, indicating it has already passed earlier safety tests. Late-stage trials typically focus more on treatment effectiveness, suggesting that MK-8748 demonstrated some level of safety in earlier research. Prospective participants should consult a healthcare provider about any concerns before joining a trial.12345Why are researchers excited about this trial's treatments?
Researchers are excited about MK-8748 for macular edema because it introduces a new approach to treatment. Unlike current options like aflibercept, which is a standard anti-VEGF therapy, MK-8748 may offer a different mechanism or formulation that could enhance effectiveness. This drug is being tested in both low and high doses, potentially providing more tailored treatment options based on individual patient needs. If successful, MK-8748 could lead to more personalized and possibly more effective management of macular edema.
What evidence suggests that this trial's treatments could be effective for diabetic macular edema?
Studies have shown that aflibercept effectively treats diabetic macular edema (DME) by reducing swelling and improving vision. It is a well-established treatment for this condition. In this trial, participants will receive either aflibercept or MK-8748. Early research on MK-8748 has shown promising results, similar to aflibercept, in reducing eye swelling and improving vision. Participants in initial trials of MK-8748 reported positive changes in their vision and eye health, suggesting it could be an effective treatment for DME. Researchers are testing both low and high doses of MK-8748 in this trial to determine the optimal dosage for these benefits.678
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for people with type 1 or type 2 diabetes who have vision loss in one eye mainly due to diabetic macular edema. Their long-term blood sugar (HbA1c) must be 12% or less. Both those new to DME treatment and those treated within the last 3 years may join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 5 initial administrations of MK-8748 or aflibercept every 4 weeks, then continue every 8 weeks until week 48. After week 48, treatment intervals are personalized based on response, up to week 100.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Aflibercept
- MK-8748
Trial Overview
The study compares a new medicine, MK-8748, against the standard treatment aflibercept to see if MK-8748 works as well for treating diabetic macular edema. Participants are randomly assigned to receive either drug.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Participants receive 5 initial administrations of MK-8748 low dose every 4 weeks (Q4W), then continue to receive MK-8748 low dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Participants receive 5 initial administrations of MK-8748 high dose every 4 weeks (Q4W), then continue to receive MK-8748 high dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Participants receive 5 initial administrations of aflibercept 2 mg every 4 weeks (Q4W), then continue to receive aflibercept 2mg every 8 weeks (Q8W) until week 100.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
https://www.clinicaltrials.gov/ct2/results?term=NC...
No information is available for this page.
Pharma Industry News and Analysis
Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a. New Data Highlighting Concurrent
FEvIR Platform
Making science machine-interpretable. FEvIR Platform You need to enable JavaScript to run this app.
Clinical Trial Update July/August 2024
Purpose: The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with diabetic macular edema.
5.
ophthalmology360.com
ophthalmology360.com/retina/persistent-macular-edema-after-anti-vegf-leads-to-worse-outcomes-in-crvo/Persistent macular edema after anti-VEGF leads to worse ...
Persistent ME by 52 weeks resulted in poorer 100-week BCVA compared with patients with dry macula and recurrent ME. By 100 weeks, 18.6% of eyes ...
6.
trial.medpath.com
trial.medpath.com/clinical-trial/5f7272e1d9937677/nct00168324-safety-efficacy-new-treatment-macular-edemaA Study of the Safety and Efficacy of a... | Clinical Trial
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with ...
7.
ctv.veeva.com
ctv.veeva.com/study/a-study-in-patients-with-neovascular-age-related-macular-degeneration-or-diabetic-macular-edema-to-eA Study in Patients With Neovascular Age-Related Macular ...
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab ...
LONG-TERM OUTCOMES OF ANTI-VEGF THERAPY
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011; ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.